RecruitingNCT05574673
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study
Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Enrollment
1,000 participants
Start Date
Dec 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 100 Years
Inclusion Criteria7
- Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:
- FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)
- FIGO stage III-IV of any histology
- Women aged ≥18 years of age at the time of diagnosis
- Patients intended for platinum-based chemotherapy treatment
- Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Patients consent to provide archival tumor tissue sample
Exclusion Criteria2
- Non-epithelial ovarian cancer, borderline tumors, or mucinous histology
- Patients with FIGO stage I-II, BRCAwt ovarian cancer
Interventions
OTHERStandard of care
Patients receive standard of care treatment according to local and national guidelines
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05574673
Related Trials
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
NCT071674331 location
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706879 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT0528147131 locations